TIDMCBX
RNS Number : 6102J
Cellular Goods PLC
28 April 2022
Press release
28 April 2022
Cellular Goods PLC
('Cellular Goods' or 'the Company')
First patent application filed for skin brightening
innovation
Cellular Goods (LSE: CBX), a UK-based wellness company that
provides premium consumer products formulated with lab-made
cannabinoids, is pleased to announce the filing of its first patent
application related to the use of cannabinoids for skin
brightening.
Internal and external factors like hormonal changes during
pregnancy and exposure to the sun can cause skin conditions such as
melasma and hyperpigmentation, that can make the skin tone change
and become uneven. Within the cosmetics and beauty industry, a
number of products have been developed to help people achieve an
even and brighter skin tone.
Most products in the skin brightening market rely primarily on
active ingredients such as Vitamin C, exfoliating acids and
hydroquinones that while effective in tackling melasma and
hyperpigmentation, can cause skin irritation and sensitivity. This
has created a need for new ingredients that are equally effective
as the components in traditional skin brightening products, but
that don't produce the uncomfortable side effects and have better
tolerability for frequent use.
To tackle this challenge, Cellular Goods conducted scientific
research to assess the potential of cannabinoids as skin
brightening ingredients. The series of research, which involved
in-vitro human tissue models, a well-established method for
assessing the effectiveness of skin brightening ingredients, found
that lab-made cannabinoids, namely cannabigerol ("CBG"), can
improve the effectiveness of certain active ingredients used in
traditional skin brightening products. These findings provide the
basis for a new class of skin brightening solutions that can
improve skin tone evenness associated with various factors, such as
melasma and hyperpigmentation.
Cellular Goods has incorporated these findings into its patent
application, 'Dermal Composition Comprising Cannabinoid and
Derivatives Thereof', filed on 26 April 2022 with the UK
Intellectual Property Office. This application is the first patent
filed by the Company and is anticipated to form part of a wider
patent portfolio driven by Cellular Goods' research into the
wellness benefits of lab-made cannabinoids.
The Company has been using research to offer customers
innovative products such as its Rejuvenating Cannabinoid Face
Serum, the UK's first CBG-based serum to prevent the signs of aging
caused by UV light exposure and inflammation.
Anna Chokina, CEO of Cellular Goods, said: " From having skin
brightening properties, through to helping prevent the signs of
aging caused by UV light exposure and inflammation, cannabinoids
have a number of skincare benefits that we are only just starting
to understand. The filing of this patent based on our own research
is part of our efforts to help unveil the benefits of cannabinoids,
as well as to develop science-backed innovations that can improve
people's wellness. We look forward to contributing to the growing
body of research on cannabinoids, particularly their skincare
benefits, while also growing our patent portfolio."
Alexia Blake, Head of Research and Product Development at
Cellular Goods, said: "We are proud to be developing the body of
research on the skin brightening qualities of cannabinoids with the
completion of our research and the filing of this patent. This work
builds on our existing research involving lab-made cannabinoids,
including the publication of a white paper on the potential
benefits that cannabinoids can have for the skin by preventing the
signs of aging caused by UV exposure and inflammation. We are
committed to continuing to develop research that will help us
better understand the unique benefits of cannabinoids and how to
effectively leverage these benefits across our product
offerings."
Forward looking statements
This announcement includes forward-looking statements which
reflect the Company's or, as appropriate, the Directors' current
views, interpretations, beliefs or expectations with respect to the
Company's financial performance, business strategy and plans and
objectives of management for future operations. These statements
include forward-looking statements both with respect to the Company
and the sector and industry in which the Company operates.
Statements which include the words "expects", "intends", "plans",
"believes", "projects", "anticipates", "will", "targets", "aims",
"may", "would", "could", "continue", "estimate", "future",
"opportunity", "potential" or, in each case, their negatives, and
similar statements of a future or forward-looking nature identify
forward-looking statements. All forward-looking statements address
matters that involve risks and uncertainties because they relate to
events that may or may not occur in the future. Forward-looking
statements are not guarantees of future performance. Accordingly,
there are or will be important factors that could cause the
Company's actual results, prospects and performance to differ
materially from those indicated in these statements. In addition,
even if the Company's actual results, prospects and performance are
consistent with the forward-looking statements contained in this
document, those results may not be indicative of results in
subsequent periods. These forward-looking statements speak only as
of the date of this announcement. Subject to any obligations under
the Prospectus Regulation Rules, the Market Abuse Regulation, the
Listing Rules and the Disclosure and Transparency Rules and except
as required by the FCA, the London Stock Exchange, the City Code or
applicable law and regulations, the Company undertakes no
obligation publicly to update or review any forward-looking
statement, whether as a result of new information, future
developments or otherwise.
For further information please contact:
Cellular Goods
Anna Chokina via Tancredi +44 207 887 7633
Chief Executive
Neil Thapar +44 787 645 5323
Investor Relations
------------------------------
Tennyson Securities
------------------------------
Corporate Broker
Peter Krens +44 207 186 9030
------------------------------
Novum Securities
------------------------------
Corporate Broker
Colin Rowbury
Jon Belliss +44 207 399 9427
------------------------------
Tancredi Intelligent Communication
------------------------------
Media Relations
Helen Humphrey
Gabriela Amaya Garcia +44 744 922 6720
Charlie Hobbs +44 791 503 5294
cellulargoods@tancredigroup.com +44 789 755 7112
------------------------------
About Cellular Goods PLC:
Cellular Goods is a UK-based wellness company that provides
premium products based on lab-made cannabinoids. It was established
in August 2018 to develop efficacy-led and research-backed
cannabinoid-powered wellness products. The initial focus is on
three product verticals: Function Better, Feel Better and Look
Better. These three verticals encompass Cellular Goods' premium CBG
skincare and CBD ingestible and topical athletic recovery products,
with the first products launched in December 2021 initially through
the Company's website. The Company's shares are listed on the main
market of the London Stock Exchange. www.cellular-goods.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUWCCUPPGRM
(END) Dow Jones Newswires
April 28, 2022 02:01 ET (06:01 GMT)
Cellular Goods (LSE:CBX)
Historical Stock Chart
From Apr 2024 to May 2024
Cellular Goods (LSE:CBX)
Historical Stock Chart
From May 2023 to May 2024